{"name":"Gruppo Italiano Studio Linfomi","slug":"gruppo-italiano-studio-linfomi","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"COPPEBVCAD vs BEACOPP vs ABVD","genericName":"COPPEBVCAD vs BEACOPP vs ABVD","slug":"coppebvcad-vs-beacopp-vs-abvd","indication":"Hodgkin lymphoma (early-stage and advanced-stage)","status":"phase_3"},{"name":"HDS vs ProMECE/CytaBOM","genericName":"HDS vs ProMECE/CytaBOM","slug":"hds-vs-promece-cytabom","indication":"Aggressive non-Hodgkin lymphoma","status":"phase_3"},{"name":"Melphalan, Prednisone and Thalidomide","genericName":"Melphalan, Prednisone and Thalidomide","slug":"melphalan-prednisone-and-thalidomide","indication":"Multiple myeloma (newly diagnosed or relapsed/refractory)","status":"phase_3"}]}],"pipeline":[{"name":"COPPEBVCAD vs BEACOPP vs ABVD","genericName":"COPPEBVCAD vs BEACOPP vs ABVD","slug":"coppebvcad-vs-beacopp-vs-abvd","phase":"phase_3","mechanism":"COPPEBVCAD, BEACOPP, and ABVD are combination chemotherapy regimens that use multiple cytotoxic agents to kill rapidly dividing cancer cells.","indications":["Hodgkin lymphoma (early-stage and advanced-stage)"],"catalyst":""},{"name":"HDS vs ProMECE/CytaBOM","genericName":"HDS vs ProMECE/CytaBOM","slug":"hds-vs-promece-cytabom","phase":"phase_3","mechanism":"HDS vs ProMECE/CytaBOM are competing chemotherapy regimens designed to treat aggressive lymphomas through different combinations of cytotoxic agents.","indications":["Aggressive non-Hodgkin lymphoma","Hodgkin lymphoma (advanced stage)"],"catalyst":""},{"name":"Melphalan, Prednisone and Thalidomide","genericName":"Melphalan, Prednisone and Thalidomide","slug":"melphalan-prednisone-and-thalidomide","phase":"phase_3","mechanism":"This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone chemotherapy with thalidomide (immunomodulatory agent) to kill myeloma cells and enhance immune response.","indications":["Multiple myeloma (newly diagnosed or relapsed/refractory)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}